دورية أكاديمية
The Role of Cytokines and Molecular Pathways in Lung Fibrosis Following SARS-CoV-2 Infection: A Physiopathologic (Re)view.
| العنوان: | The Role of Cytokines and Molecular Pathways in Lung Fibrosis Following SARS-CoV-2 Infection: A Physiopathologic (Re)view. |
|---|---|
| المؤلفون: | Lazar M; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.; National Institute for Infectious Diseases 'Prof. Dr. Matei Bals', No. 1, Calistrat Grozovici Street, Sector 2, 021105 Bucharest, Romania., Sandulescu M; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania., Barbu EC; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania., Chitu-Tisu CE; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania., Andreescu DI; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania., Anton AN; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania., Erculescu TM; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania., Petre AM; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania., Duca GT; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania., Simion V; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania., Padiu IF; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania., Pacurar CG; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania., Rosca R; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania., Simian TM; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania., Oprea CA; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania., Ion DA; Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania. |
| المصدر: | Biomedicines [Biomedicines] 2024 Mar 13; Vol. 12 (3). Date of Electronic Publication: 2024 Mar 13. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101691304 Publication Model: Electronic Cited Medium: Print ISSN: 2227-9059 (Print) Linking ISSN: 22279059 NLM ISO Abbreviation: Biomedicines Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI AG, [2013]- |
| مستخلص: | SARS-CoV-2 infection is a significant health concern that needs to be addressed not only during the initial phase of infection but also after hospitalization. This is the consequence of the various pathologies associated with long COVID-19, which are still being studied and researched. Lung fibrosis is an important complication after COVID-19, found in up to 71% of patients after discharge. Our research is based on scientific articles indexed in PubMed; in the selection process, we used the following keywords: "lung fibrosis", "fibrosis mediators", "fibrosis predictors", "COVID-19", "SARS-CoV-2 infection", and "long COVID-19". In this narrative review, we aimed to discuss the current understanding of the mechanisms of initiation and progression of post-COVID-19 lung fibrosis (PC-19-LF) and the risk factors for its occurrence. The pathogenesis of pulmonary fibrosis involves various mediators such as TGF-β, legumain, osteopontin, IL-4, IL-6, IL-13, IL-17, TNF-α, Gal-1, Gal-3, PDGF, and FGFR-1. The key cellular effectors involved in COVID-19 lung fibrosis are macrophages, epithelial alveolar cells, neutrophils, and fibroblasts. The main fibrosis pathways in SARS-CoV-2 infection include hypoxemia-induced fibrosis, macrophage-induced fibrosis, and viral-fibroblast interaction-induced fibrosis. |
| References: | Nat Rev Immunol. 2020 Jun;20(6):345-346. (PMID: 32358580) Int J Mol Sci. 2021 Dec 24;23(1):. (PMID: 35008594) Mol Biol Cell. 2001 Sep;12(9):2730-41. (PMID: 11553712) Respir Investig. 2023 Sep;61(5):601-617. (PMID: 37429073) Sci Transl Med. 2022 Nov 16;14(671):eabo5795. (PMID: 36383686) Nature. 2021 Feb;590(7847):635-641. (PMID: 33429418) Exp Cell Res. 2018 Feb 15;363(2):291-298. (PMID: 29355493) PLoS One. 2018 Dec 31;13(12):e0209786. (PMID: 30596712) Int J Mol Sci. 2022 Jul 26;23(15):. (PMID: 35897786) Sci Transl Med. 2019 Sep 25;11(511):. (PMID: 31554736) Cell Stem Cell. 2020 Dec 3;27(6):905-919.e10. (PMID: 33142113) J Clin Med. 2023 Jan 11;12(2):. (PMID: 36675530) Mol Med Rep. 2016 Aug;14(2):1297-301. (PMID: 27279470) Immunotherapy. 2022 May;14(7):521-530. (PMID: 35306855) Inflammation. 2017 Oct;40(5):1622-1630. (PMID: 28577134) Arch Bronconeumol. 2023 Feb;59(2):69-70. (PMID: 36041958) Nature. 1997 Oct 9;389(6651):631-5. (PMID: 9335507) Nat Med. 2020 Jun;26(6):842-844. (PMID: 32398875) Int J Chron Obstruct Pulmon Dis. 2018 Aug 20;13:2483-2494. (PMID: 30154651) J Hepatol. 2020 Nov;73(5):1063-1071. (PMID: 32526252) Pharmacol Rep. 2021 Dec;73(6):1539-1550. (PMID: 34176080) Am J Respir Cell Mol Biol. 2010 Aug;43(2):161-72. (PMID: 19767450) Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076) Signal Transduct Target Ther. 2021 Aug 18;6(1):308. (PMID: 34408131) Dtsch Arztebl Int. 2021 Mar 05;118(Forthcoming):. (PMID: 33531115) Respir Res. 2002;3:13. (PMID: 11806848) J Clin Invest. 2021 Jul 15;131(14):. (PMID: 34263736) Eur Rev Med Pharmacol Sci. 2021 Jun;25(12):4435-4438. (PMID: 34227081) Chest. 2021 Sep;160(3):983-993. (PMID: 33905677) Toxicol Appl Pharmacol. 2020 Mar 15;391:114913. (PMID: 32032644) J Pathol. 2013 Jan;229(2):298-309. (PMID: 22996908) Int J Antimicrob Agents. 2020 Mar;55(3):105924. (PMID: 32081636) PLoS One. 2014 Apr 15;9(4):e94188. (PMID: 24736635) Cell Stem Cell. 2017 Feb 2;20(2):261-273.e3. (PMID: 27867035) Am J Respir Cell Mol Biol. 2015 Jul;53(1):74-86. (PMID: 25409201) Cell Death Discov. 2021 Mar 15;7(1):52. (PMID: 33723241) J Leukoc Biol. 2021 Jan;109(1):55-66. (PMID: 32930456) Mediators Inflamm. 2019 Mar 27;2019:7947596. (PMID: 31049028) J Bras Pneumol. 2021 Sep 06;47(4):e20210213. (PMID: 34495179) Emerg Microbes Infect. 2020 Dec;9(1):1123-1130. (PMID: 32475230) Sci Rep. 2017 Oct 16;7(1):13281. (PMID: 29038604) Radiol Med. 2012 Mar;117(2):185-200. (PMID: 22020433) Int Immunopharmacol. 2022 Dec;113(Pt A):109409. (PMID: 36461602) Front Immunol. 2020 Aug 18;11:2069. (PMID: 32973815) Viruses. 2022 Aug 23;14(9):. (PMID: 36146648) Nature. 2022 Jun;606(7914):585-593. (PMID: 35483404) Nature. 2021 Jul;595(7865):114-119. (PMID: 33915568) Cell Death Discov. 2017 Apr 10;3:17010. (PMID: 28417017) J Mol Histol. 2022 Dec;53(6):883-890. (PMID: 36100803) Obesity (Silver Spring). 2020 Jul;28(7):1187-1190. (PMID: 32339391) Lung India. 2022 May-Jun;39(3):247-253. (PMID: 35488682) JCI Insight. 2018 Jul 12;3(13):. (PMID: 29997297) Aging (Albany NY). 2020 Apr 10;12(7):6037-6048. (PMID: 32275643) Front Immunol. 2021 Jun 14;12:663303. (PMID: 34194429) Respir Res. 2015 Jul 03;16:83. (PMID: 26138239) Int J Infect Dis. 2021 Jan;102:233-238. (PMID: 33130200) Diagnostics (Basel). 2022 Aug 22;12(8):. (PMID: 36010377) Sci Transl Med. 2021 Nov 17;13(620):eabj7790. (PMID: 34648357) J Med Virol. 2023 Aug;95(8):e29009. (PMID: 37563850) J Mol Cell Biol. 2023 Aug 3;15(4):. (PMID: 37127426) PLoS One. 2017 Sep 5;12(9):e0183972. (PMID: 28873461) Immunity. 2020 Dec 15;53(6):1258-1271.e5. (PMID: 33296686) Int J Infect Dis. 2020 Oct;99:485-488. (PMID: 32841688) Cell Rep. 2015 Mar 10;10(9):1626-1638. (PMID: 25753426) Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1336-41. (PMID: 10194186) Jpn J Infect Dis. 2021 Nov 22;74(6):530-536. (PMID: 33790073) Chin Med J (Engl). 2020 May 5;133(9):1032-1038. (PMID: 32118640) Thorax. 2018 Aug;73(8):723-730. (PMID: 29382797) Chin Med J (Engl). 2020 May 5;133(9):1087-1095. (PMID: 32358325) mBio. 2021 May 4;12(3):. (PMID: 33947753) J Infect Public Health. 2022 Oct;15(10):1072-1075. (PMID: 36088825) Biochem J. 2011 Aug 1;437(3):515-20. (PMID: 21585337) Organogenesis. 2010 Oct-Dec;6(4):225-33. (PMID: 21220961) Nat Med. 2007 Aug;13(8):952-61. (PMID: 17660828) Respir Med. 2021 Sep;186:106534. (PMID: 34260978) Int Rev Cytol. 2007;257:143-79. (PMID: 17280897) Indian J Tuberc. 2023 Apr;70(2):249-252. (PMID: 37100584) Respir Res. 2021 Jul 9;22(1):203. (PMID: 34243776) Mediators Inflamm. 2015;2015:510105. (PMID: 25944985) Front Cell Dev Biol. 2021 Jul 08;9:676150. (PMID: 34307358) Alcohol Clin Exp Res. 2014 Feb;38(2):336-43. (PMID: 24033682) Cell Death Differ. 2020 Dec;27(12):3209-3225. (PMID: 33037393) JCI Insight. 2021 Aug 9;6(15):. (PMID: 34185704) Ann Med Surg (Lond). 2022 May;77:103590. (PMID: 35411216) Am J Pathol. 2003 Jul;163(1):345-54. (PMID: 12819039) Sci Rep. 2022 Jan 24;12(1):1272. (PMID: 35075140) JCI Insight. 2019 Jul 25;5:. (PMID: 31343988) Immunol Rev. 2021 Jul;302(1):228-240. (PMID: 34028807) Dis Model Mech. 2011 Jul;4(4):469-83. (PMID: 21324930) J Cell Biol. 1990 Dec;111(6 Pt 2):3155-64. (PMID: 2269669) Medicina (Kaunas). 2022 Jul 18;58(7):. (PMID: 35888664) J Clin Med. 2023 Jun 25;12(13):. (PMID: 37445288) Cell Death Dis. 2021 Mar 26;12(4):327. (PMID: 33771973) Diabetes Metab Syndr Obes. 2020 Dec 14;13:4953-4959. (PMID: 33363393) Front Immunol. 2020 Sep 29;11:585647. (PMID: 33133104) Am J Respir Cell Mol Biol. 2022 Apr;66(4):391-401. (PMID: 34982656) Crit Care Med. 2012 Feb;40(2):510-7. (PMID: 21926573) ERJ Open Res. 2023 Apr 17;9(2):. (PMID: 37077555) Respir Res. 2020 Jul 14;21(1):182. (PMID: 32664949) Am J Physiol Lung Cell Mol Physiol. 2019 Mar 1;316(3):L487-L497. (PMID: 30604628) Cell. 2021 Dec 22;184(26):6243-6261.e27. (PMID: 34914922) Am J Respir Crit Care Med. 2016 Jul 1;194(1):84-96. (PMID: 26771871) Lancet. 2021 Aug 28;398(10302):747-758. (PMID: 34454673) PeerJ. 2020 Jun 15;8:e9392. (PMID: 32587806) J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):420-7. (PMID: 26914911) Nature. 2021 Jul;595(7865):107-113. (PMID: 33915569) Cell Chem Biol. 2023 Mar 16;30(3):261-277.e8. (PMID: 36889311) Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651) Arch Bronconeumol. 2022 Apr;58 Suppl 1:39-50. (PMID: 35501222) Ann Rheum Dis. 2018 Apr;77(4):523-532. (PMID: 29275332) Cell Signal. 2020 Feb;66:109482. (PMID: 31760172) Front Immunol. 2018 Jan 05;8:1835. (PMID: 29379497) Expert Rev Respir Med. 2021 Jun;15(6):791-803. (PMID: 33902377) Sci Rep. 2023 Jul 11;13(1):11207. (PMID: 37433819) FASEB J. 2017 Nov;31(11):4745-4758. (PMID: 28701304) J Infect. 2021 Feb;82(2):e5-e7. (PMID: 32998036) Front Immunol. 2019 May 24;10:1084. (PMID: 31178859) Dev Comp Immunol. 2016 Feb;55:221-32. (PMID: 26429410) BMC Infect Dis. 2022 Oct 14;22(1):788. (PMID: 36241980) J Biol Chem. 2023 Mar;299(3):102922. (PMID: 36669646) |
| فهرسة مساهمة: | Keywords: COVID-19; SARS-CoV-2 infection; fibrosis mediators; fibrosis predictors; long COVID-19; lung fibrosis |
| تواريخ الأحداث: | Date Created: 20240328 Latest Revision: 20240330 |
| رمز التحديث: | 20240330 |
| مُعرف محوري في PubMed: | PMC10968428 |
| DOI: | 10.3390/biomedicines12030639 |
| PMID: | 38540252 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!